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Friedreich ataxia (FRDA) is an inherited recessive disorder caused by a deficiency in the 
mitochondrial protein frataxin. There is currently no effective treatment for FRDA available, 
especially for neurological deficits. In this study, we tested diazoxide, a drug commonly used as 
vasodilator in the treatment of acute hypertension, on cellular and animal models of FRDA. We first 
showed that diazoxide increases frataxin protein levels in FRDA lymphoblastoid cell lines, via the 
mTOR pathway. We then explored the potential therapeutic effect of diazoxide in frataxin-deficient 
transgenic YG8sR mice and we found that prolonged oral administration of 3mpk/d diazoxide was 
found to be safe, but produced variable effects concerning efficacy. YG8sR mice showed improved 
beam walk coordination abilities and footprint stride patterns, but  a generally reduced locomotor 
activity. Moreover, they showed significantly increased frataxin expression, improved aconitase 
activity and decreased protein oxidation in cerebellum and brain mitochondrial tissue extracts. 
Further studies are needed before this drug should be considered for FRDA clinical trials.  
 
INTRODUCTION 
Friedreich ataxia (FRDA, OMIM 229300) is an autosomal recessive disorder due to an increase in 
the number of GAA trinucleotide repeats within the first intron of the FXN gene on chromosome 9 
(1). Normal individuals have 5 to 30 GAA repeats, whereas affected individuals have 70 to more 
than 1000 GAA triplet expansions, causing decreased gene expression. FRDA occurs with a 
prevalence of approximately 1/50,000 in Caucasian populations and it is characterized clinically by 
an onset in the first two decades of life with limb ataxia, cerebellar dysarthria, lack of deep-tendon 
reflexes, pyramidal signs, and sensory loss. Most patients have degeneration of the sensory neurons 
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in the dorsal root ganglia (DRG) and cerebellum, together with skeletal deformities and 
hypertrophic cardiomyopathy. There is also an increased incidence of blindness, deafness, and 
diabetes mellitus, suggesting that the disorder is not limited to the nervous system. The severity of 
clinical features in FRDA is related to the GAA trinucleotide repeat length (2). Symptoms begin 
usually in childhood (5–15 years), but onset may vary from infancy to adulthood (3). The FXN gene 
encodes the mitochondrial protein frataxin, which is involved in mitochondrial iron metabolism, 
assembly of iron-sulphur proteins and heme synthesis (4). The exact physiological function of 
frataxin is unknown, but there is general agreement that it is involved in cellular iron homeostasis 
and that its deficiency results in multiple enzyme deficits, mitochondrial dysfunction and oxidative 
damage (5-7). There is no available effective treatment for FRDA, especially for neurological 
features. In fact, antioxidant agents, such as idebenone, a short-chain analogue of coenzyme Q10, 
and iron chelators, which have been used as potential therapeutic agents, ameliorate mitochondrial 
oxidative stress but have no effects on neurological symptoms (8). Since the disorder is caused by 
deficiency of FXN gene expression, a possible therapeutic strategy could be the stimulation of 
frataxin expression with exogenous substances to increase its level (9). Several molecules are 
reported to increase frataxin mRNA or protein levels. However, no clear results supporting a benefit 
of any of these drugs have so far been obtained in randomized controlled trials (10). Here, we study 
the effect of diazoxide on cell lines from FRDA patients and on the YG8sR FRDA mouse model 
(11). Diazoxide is a potassium channel opener, active mainly on the mitochondrial ATP-sensitive 
potassium channel (mito-KATP channel) (12), which has been in use for over 50 years as a 
vasodilator in the treatment of acute hypertension (13). It is the active ingredient in Proglycem, a 
nondiuretic benzothiadiazine derivative taken orally for the management of symptomatic 
hypoglycaemia (14). Particularly, we studied the effect of diazoxide, to increase frataxin expression 
levels and to ameliorate the functional and biochemical features of a FRDA mouse model. 
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Diazoxide induces frataxin expression in FRDA patient lymphoblastoid cells 
We analyzed three lymphoblastoid cell lines from FRDA patients (P119, P200, P338) with different 
GAA repeat expansions, representing: (i) a mild phenotype with late onset and 170/230 GAA 
repeats (P338); (ii) a canonical phenotype with 500/800 GAA repeats (P119) and (iii) a severe 
phenotype with early onset and 1100/1100 GAA repeats (P200). As shown in Fig. 1A, the amount 
of frataxin protein was virtually undetectable in each of the cell extracts (20 µg). First we test the 
effect of different diazoxide concentrations on cell viability and we found no toxicity of diazoxide 
for all cell lines unless they were incubated in the presence of 400 µM or higher concentrations, for 
at least 4 days (Fig. 1B). Frataxin expression was measured upon incubating cell cultures in 
presence of 100 µM diazoxide (D), 100 µM diazoxide and 20 mM glucose (GD), or vehicle alone 
(NT). Cells were collected after 4 days of treatment. We used glucose in combination with 
diazoxide because the effect of mitoKATP channel openers is exerted only on the ATP-bound 
potassium channel and depends by the energetic state of the cells (12). Immunoblots of total cell 
lysates revealed a significant frataxin increase for all cells with D and DG treatments, compared to 
vehicle-treated cells (NT), ranging from 80 to 300% induction (Fig. 2A-B). The addition of glucose 
produced minimal increases in frataxin expression compared to diazoxide alone (Fig. 2A). 
Immunoblots of frataxin from total cell lysates of healthy control cell line revealed no significant 
differences (Fig. 2C). 
 
Diazoxide induces frataxin expression and decreases oxidative cell damage in YG8sR FRDA 
mouse model 
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To test the effect of diazoxide on living organism, we used the YG8sR FRDA mouse model (11). 
This model is a new line of GAA-repeat-expansion-based FRDA mice derived from YG8R 
breeding, which contains a single copy of the human FXN transgene and a single pure GAA repeat 
expansion mutation, which was 120 GAA repeats in size in the founder mouse. These mice exhibit 
an age-dependent GAA repeat expansion accumulation in the CNS, particularly the cerebellum, 
progressive decrease in motor coordination and significant functional locomotor deficits, features 
similar to those observed in FRDA patients. In addition, the YG8sR mice exhibit the presence of 
pathological vacuoles within neurons of the dorsal root ganglia, together with reduced levels of 
brain aconitase activity, in line with an FRDA-like phenotype. Therefore, these YG8sR mice 
currently represent the most suitable GAA-repeat-based YAC transgenic mouse model to explore 
potential FRDA therapies. First, we observed that treatment of YG8sR mice p.o. daily for 5 days 
with 10 mg/kg diazoxide was safe and no adverse effects were observed with any mice. Since short-
term treatment did not produce neither down-stream effects (data not shown), nor an increase of 
frataxin expression (data not shown) we extended the period of diazoxide treatment to three months. 
Groups of 20 YG8sR mice (10 male and 10 female, 4 months old) were treated p.o. daily for three 
months with either vehicle (1% DMSO) or 3mg/kg diazoxide, followed by collection of snap-frozen 
brain, cerebellum, heart, liver and pancreas tissues. Quantitative RT-PCR (qRT-PCR) analysis of 
FXN mRNA expression of cerebellum and heart tissues from YG8sR mice revealed statistically 
significant differences between diazoxide-treated and vehicle-treated groups of mice (p<0.05) (Fig. 
3A), which translated into 2.6-fold and 1.6-fold increases in FXN expression levels, respectively, in 
diazoxide-treated mice (Fig. 3B).  
Similarly, significant 1.4 to 2.8-fold increases in frataxin protein levels were detected by western 
blot densitometry analysis of mitochondrial extracts from heart (p<0.01), cerebellum (p<0.05) and 
brain (p<0.05) tissues from YG8sR mice (Fig. 4A-B).  We also tested the activity of mitochondrial 
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aconitase, an iron-sulphur protein involved in iron homeostasis, that is deficient in FRDA cells. A 
significant increase in aconitase activity, was detected in YG8sR brain tissue (p<0.05), together 
with trends to increase in other tissues (Fig. 5A). Furthermore, oxyblot analysis revealed a 
significant reduction (p<0.05) in protein oxidation levels in YG8sR brain, pancreas and liver tissues 
and trends to decrease in other tissues (Fig. 5B). 
 
Diazoxide effect on functional behaviour of the YG8sR FRDA mouse model 
 
To investigate the ability of oral diazoxide to ameliorate the functional behaviour of the YG8sR 
FRDA mouse model, groups of 20 mice (10 male and 10 female) were given either 3mg/kg/d 
diazoxide or vehicle (1% DMSO) p.o. ad libitum in drinking water for a period of three months 
from approximately 4 months of age. This dose of diazoxide was well tolerated and no adverse 
effects were observed with any mice. Furthermore, there were no significant differences in weight 
detected between diazoxide-treated (D) and vehicle-treated (V) groups of YG8sR mice (Fig. S1). 
Functional behavioral studies were performed on all mice, including rotarod analysis (monthly), 
beam breaker locomotor open field testing (monthly), beam walking (start and end of study), and 
footprint analysis (start and end of study). Rotarod analysis did not reveal any significant 
improvement in the performance of YG8sR mice throughout three months of treatment with 
diazoxide compared with vehicle treatment (Fig. 6A). Beam breaker locomotor analysis identified  
a general slowing down of movement of diazoxide-treated YG8sR mice compared with vehicle-
treated mice from 5-7 months of age, as exemplified by the relative reductions of average velocity 
(2 way ANOVA p<0.01), no change in the amount of jumping (2 way ANOVA p<0.01), but an 
increase in the amount of rearing up onto hind limbs, as shown by a relative increase in vertical 
counts (2 way ANOVA p<0.001) and in vertical time on diazoxide treatment (2 way ANOVA 
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p<0.01), from month 1 to month 3 of the study (Fig. 6B-E). Beam walk analysis revealed the most 
significant diazoxide-induced functional effect for YG8sR mice (Fig. 7A). The time taken for mice 
to cross a 22mm-diameter 90cm-long beam significantly increased over the three-month test period 
for vehicle-treated YG8sR mice, indicating an increased difficulty in performing this task with age. 
Interestingly, the time taken to cross the beam significantly decreased over the three-month time 
period for diazoxide-treated YG8sR mice and there were significant differences between diazoxide-
treated and vehicle-treated groups at the three months time point, indicating much improved 
coordination abilities of YG8sR mice (Fig. 7A). Footprint analysis revealed a significant reduction 
in the stride length of diazoxide-treated YG8sR mice compared with vehicle-treated YG8sR mice 
over the three-month test period (Fig. 7B, S1), whereas the hind limb base width for YG8sR mice 
was not affected by diazoxide treatment (Fig. S1-2). 
 
Diazoxide activates the TOR pathway and promotes nuclear Nrf2 translocation 
Literature data showed the ability of diazoxide to activate mTOR kinases (15). To investigate the 
involvement of the mTOR pathway in the FXN expression, we first analyzed the activation of 
mTOR kinases in our cell lines. The amount of phosphorylated form of S6K, a target of mTOR 
kinase (16), was increased after diazoxide treatment (Fig. 8A), confirming the positive effect of 100 
µM diazoxide on mTOR pathway. This increase was almost abolished by the addition of 2 nM 
rapamycin (Fig. 8A), a well-known inhibitor of mTOR kinases (17). To link this effect to the FXN 
expression, we analyzed the amount of FXN in diazoxide-induced cell cultures, by using 
rapamycin. We found that treatment with 2 nM rapamycin completely inhibited the frataxin-
increasing effect elicited by diazoxide (Fig. 8B). The antioxidative response exerted by the 
activation of mTOR pathway has been recently linked to the activation of nuclear factor E2-related 
factor 2 (NRF2), a transcription factor ubiquitously expressed that regulates cellular redox 
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homeostasis (18). We observed that induction of frataxin expression is mediated by NRF2 
transcription factor, because diazoxide treatment also increased the NRF2 expression in cerebellum 
tissues of mouse model (Fig. 3). In order to elucidate the effect of diazoxide on the activation of 
antioxidative pathways exerted by nuclear NRF2 in lymphoblastoid cell lines, we performed an 
analysis of Nrf2 nuclear translocation. Immunoblotting analysis, 24h after diazoxide treatment, 
demonstrated an increase of Nrf2 signal in the nuclear fraction of lymphoblastoid cells treated with 
diazoxide (D) or with diazoxide and glucose (GD) (Fig. 8C-D). We observed a significant increase 
(p<0.05) of 1.62±0.20% and 1.66±0.28% in the relative nNRF2/cNRF2 signals in D and DG 
samples, respectively (Fig. 8C-D). 
DISCUSSION 
A number of laboratories have focused on small molecule activators of FXN gene expression as 
potential therapeutic agents. There are several molecules that increase frataxin mRNA or protein 
levels (9). Due to chromatin structural changes and histone deacetylation, HDAC inhibitors may 
revert heterochromatin activating the right conformation and restoring the normal function of 
silenced frataxin gene (19-21). A different strategy is the increase of the amount of frataxin protein 
by a post-transcriptional mechanism. Recombinant human erythropoietin has been reported to 
increase the level of frataxin in lymphocytes from FRDA patients and in various human cell lines 
(22). The molecular basis for this observation is unknown, but it has been proposed to depend on 
increased stabilization of frataxin protein because the level of frataxin mRNA is the same in treated 
and untreated control cells. In this study we investigated the possible role of diazoxide on frataxin 
expression. Diazoxide is a pharmacological agent derived from benzothiazine and it is an activator 
of the mitochondrial K
+
 channels, causing the opening of channels, and in medical practice it is a 
drug normally used for acute hypertension therapy. Diazoxide activates the mitochondrial ATP-
dependent potassium channels (mitoKATP) composed by a potassium channel subunits (Kir6.2) 
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together with the regulatory subunit sulphonylurea receptor (SUR) (12). These channels can 
potentially modulate the tightness of coupling between respiration and ATP synthesis, ROS 
production, mitochondrial dynamics and mitophagy (12 and references therein). MitoKATP is 
involved in the regulation of mitochondrial ionic homeostasis and, importantly, its activation has 
been observed to provide cytoprotection against ischemic damage (23, 24). In our study, we tested 
the effect of diazoxide in vitro, using lymphoblastoid cell lines from FRDA patients and in vivo, 
using the YG8sR mouse model. Cells derived from FRDA patients carry the complete frataxin 
locus together with GAA repeat expansions and regulatory sequences. They are easily accessible 
and constitute one of the most relevant frataxin-deficient cell models. We used three different cell 
lines with different number of GAA expansions (170/230 GAA repeats for P338, 500/800 GAA 
repeats for P119 and 1100/1100 GAA repeats for P200). We used a diazoxide concentration of 100 
µM, which is the approximate human blood concentration of diazoxide after an oral administration 
of 600 mg (25), and we treated lymphoblastoid cells derived from FRDA patients with diazoxide, 
alone or in presence of glucose, because the effect of mitoKATP channel openers on mitochondrial 
function is dependent by the cell’s energetic state, activating only the ATP-bound potassium 
channel (12). We found that diazoxide, alone or in combination with glucose, was able to induce the 
expression of frataxin protein in all three FRDA cell lines, after 4 days. Preliminary results show 
that the effect of diazoxide in increased frataxin protein in cell lines is higher after 4 days. We did 
not observe any increase of protein amount after 1 day, but mRNA increase of FXN expression is 
detectable after 24 hours (data not shown). The probable mechanism involves activation of the 
mTOR pathway, since rapamycin treatment of cell cultures completely blocked the ability of 
diazoxide to significantly enhance the frataxin expression. 
The relationship between frataxin expression and the mTOR pathway has recently been revealed by 
Franco et al. (26). They found that frataxin stimulation by IGF-1 was mediated by the 
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PI3K/Akt/mTOR pathway. Using either the PI3kinase inhibitor Ly294002, which prevents Akt 
activation, or rapamycin, the stimulatory action of IGF-1 was blocked. In addition, IGF-1 increases 
levels of phosphorylated mTOR, an indirect measurement of its activity status, whereas other 
kinases downstream of the IGF-1 receptor, such as PKC, are not involved in increasing frataxin 
expression after IGF-1 treatment (26). 
We then focused on determining the therapeutic efficacy of diazoxide to increase frataxin 
expression levels and to ameliorate the functional and biochemical disease effects of a FRDA 
mouse model. While cell models rarely represent tissue-specific disease features, we used a mouse 
model with residual frataxin expression, the YG8sR mouse, to investigate the effect of diazoxide in 
different tissues. These novel GAA-repeat-expansion-based YAC transgenic FRDA mice, which 
exhibit progressive FRDA-like pathology, represent an excellent model for the investigation of 
FRDA disease mechanisms and therapy, as they present an increased somatic GAA repeat 
instability in the brain and cerebellum, together with a significantly reduced expression of frataxin, 
reduced aconitase activity and a presence of pathological vacuoles in DRG that suggests autophagy 
of damaged mitochondria (11). We treated the mice with diazoxide by oral administration, because 
it is known that oral diazoxide crosses the blood-brain barrier fairly rapidly in rats, reaching a 
plateau by the fourth hour as demonstrated by cerebrospinal fluid analysis (27). Daily dosage of 
diazoxide was well tolerated and no adverse effects were observed with any of the mice, and at the 
end of the study. However, unlike lymphoblastoid cell experiments, a 5 day treatment (short-term) 
did not produce neither an increase of frataxin expression, nor other down-stream effects. By 
contrast, three months of treatment significantly improved frataxin expression in cerebellum, brain 
and heart mitochondrial tissue extracts, although the variability in frataxin increase is high amongst 
different samples. These data suggest that the effect of diazoxide on frataxin expression is not 
constant and this should be considered for future translational studies. Probably, single dosage of 
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the treatment could impair the  drug effect, and this could also explain different effects observed 
between short-term treated mice and FRDA cells. In humans for example, diazoxide are 
metabolized by oxidation and sulfate conjugation and excreted in urine (28). The half-life of 
diazoxide is about 21 hours, and usual maintenance dosage of 3–8 mg/kg is daily divided in 2 or 3 
equal doses every 8 to 12  hours (29 and references therein). Instead, diazoxide concentration in cell 
culture medium is constant, as it is not metabolized by lymphoblasts. YG8sR mice also showed an 
increase of aconitase activity, significant only in brain and a significantly decreased protein 
oxidation in brain, pancreas and liver mitochondrial tissue extracts, but only a trend to decrease in 
cerebellum and heart tissues. This suggests a different sensitivity of the tissues to oxidative stress, 
or a different half-life of frataxin that has been degraded through the proteasome (30). Further 
studies will be required to clarify these differences. Long-term treatment also revealed effects 
concerning efficacy of diazoxide on functional studies. Beam walk analysis, a test for the 
coordination abilities, revealed the most significant diazoxide-induced functional effect for YG8sR 
mice after three months of treatment. Also footprint analysis revealed a significant reduction in the 
stride length of diazoxide-treated YG8sR mice compared with vehicle-treated YG8sR mice over the 
three-month test period. Both analyses suggest a positive effect of diazoxide on the coordination 
abilities. On the contrary, locomotor analysis identified a generally reduced locomotor activity of 
diazoxide-treated YG8sR mice compared with vehicle-treated mice, although treated mice showed 
an increase in the amount of rearing up onto hind limbs. This behavior suggests the possible 
involvement of dopamine receptors that are known to be regulated by KATP channels (31). In fact, 
mice lacking dopamine D4 receptors show improved coordination abilities but decreased locomotor 
activity and rearing behavior (32). According to the presence of functional KATP channels on 
dopaminergic axons, diazoxide treatment suppressed single-pulse evoked dopamine release (31). 
This adverse effect of diazoxide should be considered for future therapeutic strategy. The hind limb 
base width and the weight of YG8sR mice was not affected by diazoxide treatment. We observed an 
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increase in weight in all mice over three months. The increase in weight is observed in FRDA mice 
in comparison to the healthy control (33). Usually, the increase in weight may be attributed to the 
decreased locomotor activity of the mice, but Tomassini et al. found that increase of FXN 
expression and amelioration in locomotor activity and motor coordination due to IFNg treatment, 
occurred independently of body weight changes (34). 
Our results suggest that the protective effects of diazoxide mediated by a stimulatory effect on 
frataxin expression, as observed in cell culture experiments and in brain and cerebellum of YG8sR 
tissues, are sufficient to ameliorate the coordination abilities. Neuroprotective effects of diazoxide 
have been well documented in conditions of ischemia and hypoxia (35, 36). It has been shown to 
promote myelination in the neonatal brain and attenuate hypoxia-induced brain injury in neonatal 
mice (37) as well as oligodendrocyte differentiation in neonatal mouse brain (38). 
The involvement of the mTOR signaling pathway as a possible mechanism by which diazoxide can 
induce frataxin expression is confirmed by the increase of S6K phosphorylation and by the 
treatment of rapamycin that completely inhibited the frataxin-increasing effect elicited by diazoxide 
(16). Kwon et al. found that (
3
H)thymidine incorporation in adult rodent islets chronically exposed 
to glucose is largely mediated through mTOR via the KATP channel, and 250 µM diazoxide 
enhanced the ability of elevated glucose to stimulate cell proliferation and S6K1 phosphorylation, a 
known target of mTOR kinases (15). The authors also demonstrated that 25 nM rapamycin 
completely inhibited the effect of diazoxide. A possible downstream target of mTOR signalling 
could be the NRF2 transcription factor mediated pathway. Activation of the NRF2 pathway induces 
frataxin expression as demonstrated by Sahdeo and colleagues (39). They found seven potential 
Nrf2-binding sites (AREs) between 20 kb upstream and 5 kb downstream of the FXN locus, three 
of them, located upstream of the transcription start site for FXN, with excellent ARE scores. They 
demonstrated by chromatin Immunoprecipitation (ChIP) experiments that they are active and 
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functional Nrf2-binding sites (39). The increase of frataxin protein may be achieved, at least in part, 
by a transcriptional mechanism, since qRT-PCR analysis of FXN mRNA revealed increases in 
expression of cerebellum and heart tissues from YG8sR mice, together with increases in Nrf2 
expression. We also demonstrated that activation of the mTOR pathway in diazoxide-treated cell 
lines induces Nrf2 nuclear translocation, and this process is inhibited by rapamycin. Our data are in 
agreement with a recent study by Virgili and colleagues who showed that diazoxide prevents 
endogenous oxidative damage of NSC-34 motoneurons after different neurotoxic insults and 
increases Nrf2 nuclear translocation (40). This study suggests that diazoxide is able to induce FXN 
expression in human cells from FRDA patients and in brain, cerebellum and heart tissues of YG8sR 
mice. Positive effects have also been observed on oxidative stress protection and coordination 
abilities of treated mice but further studies are needed to clarify the variable effects concerning 
functional studies. 
 
MATERIAL AND METHODS 
Cell lines and culture conditions 
Human control and FRDA lymphoblastoid cell lines were maintained in RPMI 1640 supplemented 
with 8 mM glutamine, 2 mM sodium pyruvate, 1x non-essential amino acids, 15% foetal bovine 
serum, and 100 U/ml penicillin and 0.1 mg/ml streptomycin. All cell lines were cultured at 37°C in 
a humidified atmosphere containing 5% CO2 in 25 cm
2
 culture flasks (kept in an upright position). 
Antibiotics were omitted during pharmacological compound assays. Cells were treated for 4 days 
with 100 µM diazoxide, alone or combined with 20 mM glucose or 2 nM rapamycin. Medium with 
reagents were changed every day during the treatment period. Nrf2 level was determined in nuclear 
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protein extracts from lymphoblastoid cell cultures 24 h after treatments, using 4 wells from 24-well 
plates for each experimental condition. 
 
Cytotoxicity  Assay 
Potential cytotoxic effects of diazoxide were carried out on lymphoblastoid cell lines using MTT (3-
[4,5-dimethylthiazol-2-yl]-2,5 diphenyl tetrazolium bromide) assay. Cells were seeded into 6 well 
plates at a density of 2.5x10
5
 cells per well in 1 mL of RPMI medium and incubated for 4 days in 
5% CO2 environment at 37 °C. The assay is based on the mitochondrial activity of living cells to 
convert water soluble MTT into water insoluble formazan crystals due to the reductive activity of 
mitochondria. Cells were incubated for 4 days in the presence of the test agent at four dilutions 
ranging from 50 to 400 µM. The assay was carried out as elsewhere described (15, 41). The 
experiment was carried out in triplicate, after 4 days. 
 
Tissue processing 
Homogenate of each tissue was prepared suspending 200 mg of tissue in a buffer containing 250 
mM sucrose, 1 mM EGTA and 10 mM TRIS pH7.4 and using a Teflon glass potter. Cell debris was 
pelleted by centrifugation at 800xg and discarded. Mitochondria from tissue homogenates were 
harvested by centrifugation at 13,000xg for 12 min at 4 °C. Mitochondria enriched pellets was then 
stored at -80 °C until further processing. 
 
Quantitative reverse transcriptase PCR 
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Total RNA was isolated from the mouse tissues by homogenisation with Trizol (Invitrogen), 
followed by DNase I treatment, and cDNA was then prepared by using AMV reverse transcriptase 
(Invitrogen) with oligo (dT)20 primers and quantified by Nanodrop (ThermoScientific) analysis 
(42). Levels of human transgenic FXN or mouse Nrf2 mRNA expression were assessed by qPCR 
using an Quant Studio 7 detection system and SYBR
®
 Green (Applied Biosystems) with the 
following primers: (1) FXN: FRT-I forward 5'-TTGAAGACCTTGCAGACAAG-3' and RRT-II 
reverse 5'-AGCCAGATTTGCTTGTTTGG-3', 121 bp amplicon size; (2) Nrf2: forward 5'-
TTTTCCATTCCCGAATTACAGT-3' and reverse 5'- GGAGATCGATGAGTAAAAATGGT-3', 
126 bp amplicon size. For each sample, assays were performed in triplicate. 
 
Western blot analysis 
Lymphoblastoid cells were washed three times, lysed with cell lysis buffer (0.15 M NaCl, 5 mM 
EDTA, 1% NP-40, 10 mM Tris-Cl, pH 7.4) and transferred to a microcentrifuge tube. For Nrf2 
analysis, cytoplasmic and nuclear fractions were separated by using the NE-Nuclear and 
Cytoplasmic Extraction kit (Thermo Fisher) by following the manufacturer’s protocol. Protein 
concentration was determined using the BCA protein assay reagent (Thermo Scientific). 20 µg of 
mouse mitochondrial protein or 80 µg of human cell proteins were separated on BOLT BIS-TRIS 
PLUS 12% polyacrylamide gels (43) and electroblotted onto nitrocellulose membranes (Thermo 
Fisher). Membranes were washed 20 min with TBST buffer and incubated with anti-frataxin (Santa 
Cruz Biotechnology, 1:500), anti-Nrf2 (Thermo Fisher, 1:500), anti-S6K1 (phospho T389; 1:500), 
anti-laminA (BD Bioscience, 1:500), anti-βATPase (BD Bioscience, 1:10,000) primary antibodies. 
Anti-NRF2, anti-laminA and anti-frataxin were incubated for 12 hours at 4°C. Anti-βATPAse and 
anti-S6K were incubated for 1 h at RT. Membranes were washed three times with TBS for 15 min, 
and then incubated for 1h at RT with anti-mouse (Pierce, 1:10,000) and anti-rabbit (Pierce, 1:5,000) 
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HRP secondary antibodies (Thermo Fisher). Finally, membranes were washed three times with TBS 
and immunoreactive bands were visualized using Immobilon Western Chemiluminescent HRP 
Substrate (Millipore)( 44). The intensity of protein bands was quantified by using QuantityOne 
4.6.3 Image software (ChemiDoc XRS; Bio-Rad) and normalized against proper loading controls 
(45, 46). 
 
Quantification of mitochondrial protein oxidation 
Carbonylated mitochondrial proteins were detected using the OxyBlot Protein Oxidation Detection 
Kit (MILLIPORE). 2,4 dinitrophenylhydrazine- derivatized crude mitochondrial protein extracts 
(10 µg) were dot blotted, incubated with a primary antibody against DNP-hydrazone followed by a 
horseradish peroxidase-conjugated secondary antibody, visualized using the ECL chemiluminescent 
detection method and quantified by densitometry (47). 
 
Enzymatic assays 
Citrate synthase activity was determined following the rate of 5,5’-dithiobis-(2-nitrobenzoic) acid 
(DTNB) consumption, as described (48). The CoA produced in the reaction mix reacts with the 
DTNB to form 5-thio-2-nitrobenzoic acid (TNB), a yellow product observed spectrophotometrically 
by measuring absorbance at 412 nm. 10 µg of mitochondrial proteins from each tissue were used for 
spectrophotometric assay using Cary win 50 UV- Spectrophotometer. Aconitase activities were 
determined according to the method described previously (23). Briefly, mitochondria were lysed in 
Tris-HCl (pH 7.4) containing 0.5% Triton X-100 and 2.5 mM sodium citrate, for 5 minutes on ice. 
Insoluble material was removed by centrifugation (14000 x g, 40 sec), and protein concentration 
was determined with Bradford reagent (Bio-Rad, Milan, Italy). 100-300 ug of mitochondrial extract 
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were added to a substrate mix (50 mM Tris/HCl pH 7.4, 0.2 mM NADP
+
, 5 mM Na citrate, 0.6 mM 
MgCl2, 0.1% (v/v) Triton X-100 and 1-2 units of isocitrate dehydrogenase) and the reactions were 
incubated at 25°C for 15 minutes, followed by spectrophotometric absorbance measurements at 340 
nm. In samples of low aconitase activity, an initial lag in NADPH formation is seen, probably due 
to a delayed accumulation of cis-aconitate (49). Thus, the determinations of aconitase activity were 
determined using linear rates during the latter half of a 60-min assay. 
 
Animal procedures and behavioural assessments 
YG8sR mice were assessed from 4 months of age for a period of 3 months. Weight determination, 
rotarod performance and beam breaker locomotor performance were assessed monthly, while beam 
walk performance and footprint analysis were assessed at the start and end of the test period, using 
previously described methodology (11). All procedures were carried out in accordance with the UK 
Home Office Animals Scientific Procedures Act (1986) and with ethical approval from the Brunel 
University London Animals Welfare and Ethical Review Board.  
 
Statistical analysis 
Statistical analysis was performed using the paired Student’s t test when comparing two groups or a 
two-way ANOVA when comparing multiple groups. Differences with p < 0.05 were assumed to be 
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FIGURE LEGENDS  
Fig 1. 100 µM diazoxide is not toxic for FRDA lymphoblastoid cells. (A) Immunoblot of FXN 
from 20 µg total cell lysates of lymphoblasts of three FRDA patients (P119, P200, P338) and 
healthy control (C). Subunit β of ATP synthase was used as loading control.  (B) Cell viability of 
lymphoblasts cells lines. Lymphoblasts from three FRDA patients (P119, P200, P338) were treated 
for 4 days with different diazoxide concentrations.  Results demonstrated that 100 µM diazoxide is 
not toxic for cells. Results expressed as mean ± SD (* p<0.05, ** p<0.01 Student’s t test, n=4). 
 
Fig 2. Diazoxide induces FXN in cultured FRDA lymphoblastoid cells. (A) Lymphoblasts from 
three FRDA patients (P119, P200, P338) were incubated in presence of 100 µM diazoxide (D), 100 
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µM diazoxide and 20 mM glucose (GD), or vehicle alone (0.1% DMSO) (NT). Total protein was 
collected after 4 days, and lysates (80 µg) were probed by western blot analysis for FXN expression 
and normalized to subunit β of ATP synthase. The plotted data represent the mean fold change in 
FXN protein in drug-treated cells, normalized to vehicle control (*p<0.05, **p<0.01 Student’s t 
test, n=4). (B) and (C) Representative blots are shown for FRDA patient (B) or healthy control (C) 
lymphoblast cell lines treated as above. 
 
 
Fig 3. Diazoxide induces FXN and NRF2 expression in YG8sR cerebellum and heart tissues.  
QRT-PCR analysis of transgenic FXN and NRF2 mRNA levels in YG8sR cerebellum and heart 
tissues. Expression data (A) and  fold changes (B) of FXN and NRF2 mRNA levels of diazoxide-
treated tissues (D) relative to those of vehicle-treated tissues (V), using the formula x=2
(∆Ct)
 and 
adjusting for input cDNA concentrations. 
 
Fig 4. Diazoxide induces FXN in YG8sR cerebellum, brain and heart tissues.  (A) Tissues from 
a group of treated (n=8) or untreated (n=8) mice were analyzed for the FXN protein expression. 20 
µg mitochondrial protein extracts from cerebellum (C), brain (B), heart (H), pancreas (P) and liver 
(L) tissues of YG8sR mice treated with p.o. daily for three months with either vehicle (1% DMSO) 
(open bars) or 3mg/kg diazoxide (grey bars) were probed by western blot analysis for FXN 
expression and normalized to subunit β of ATP synthase. The plotted data represent the mean fold 
change in FXN protein in drug-treated tissues, normalized to vehicle control in three independent 
experiments (**p<0.01, *p<0.05 Student’s t test, n=3). (B) A representative blot is shown for 
cerebellum (C), brain (B), heart (H), pancreas (P) and liver (L) tissues of YG8sR mice treated as 
above. 
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Fig 5. Diazoxide decreases oxidative stress in YG8sR mice. (A) Mitochondria purified from 
brain, heart, pancreas and liver tissues of YG8sR mice treated with p.o. daily for three months with 
either vehicle (1% DMSO) (open bars) or 3mg/kg diazoxide (grey bars) were tested (A) for 
aconitase activity (**p<0.01, Student’s t test, n=3), or (B) for oxyblot analysis (**p<0.01, Student’s 
t test, n=3). 
 
Fig 6. Diazoxide reduces locomotor activity of YG8sR mice. (A) Rotarod performance of mice, 
measured at monthly intervals. (B-E) Beam breaker locomotor analysis at monthly intervals, 
measured as fold changes in performance from month 1 to month 3. B: average velocity; C: jump 
counts; D: vertical counts; E: vertical time. Each parameter was measured four times for each 
mouse (*p<0.05, ***p<0.001, Student’s t test, n=20). 
 
Fig 7. Diazoxide improves YG8sR mice coordination. (A) Beam walk analysis, determining the 
average times taken for mice to cross a 22mm diameter beam, before and after diazoxide or vehicle 
treatment. (B) Footprint analysis, determining the average stride length of mice, before and after 
diazoxide or vehicle treatment. Each parameter was measured four times for each mouse (*p<0.05, 
***p<0.001, Student’s t test, n=20). 
 
Fig 8. Diazoxide induces FXN expression through mTOR pathway and NRF2 nuclear 
translocation in cultured FRDA lymphoblastoid cells. (A) The induction of mTOR pathway 
exerted by diazoxide was tested by treating lymphoblast cell lines from FRDA patient (P200) with 
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100 µM diazoxide (D), 100 µM diazoxide and 20 mM glucose (DG), 100 µM diazoxide, 20 mM 
glucose and 2nM rapamycin (DGR), or vehicle alone (0.1% DMSO) (NT). 20 µg of proteins from 
cellular or nuclear fractions were separated by SDS-PAGE and transferred to nitrocellulose 
membranes and probed for phosphorylated form of S6K and normalized to subunit β of ATP 
synthase.  (B) To test if the mTOR kinases are involved in the mechanism of FXN induction, 
lymphoblast cell lines from FRDA patient (P200) were treated with 100 µM diazoxide and 20 mM 
glucose (GD), 100 µM diazoxide, 20 mM glucose and 2nM rapamycin (GDR), 100 µM diazoxide 
(D), 100 µM diazoxide and 2nM rapamycin (DR), or vehicle alone (0.1% DMSO) (NT). Total 
protein was collected after 4 days, and lysates were probed by western blot analysis for FXN 
expression and normalized to subunit β of ATP synthase. (C) For the analysis of Nrf2 nuclear 
translocation, lymphoblast cell lines from FRDA patient (P200) were treated with 100 µM 
diazoxide (D), 100 µM diazoxide and 20 mM glucose (DG), or vehicle alone (0.1% DMSO) (NT) 
for 24 h. Cellular and nuclear fractions were normalized to subunit β of ATP synthase and laminA, 
respectively. (D) The ratio of Nrf2 nuclear and cellular content of samples treated as above was 
calculated and displayed in the histograms (*p<0.05, Student’s t test, n=3). 
 
S1 Fig. Weight of YG8sR mice (n=20). 
S2 Fig. Footprint images. Representative images of the footprint analysis at baseline and post-
treatment time points are shown. The scale bar = 1cm.  
S3 Fig. Footprint analysis. Hind limb base width of YG8sR mice before and after diazoxide or 
vehicle treatment (n=20).  Representative images of the footprint analysis at baseline and post-
treatment time points are shown in S2 Fig. The scale bar = 1cm. 
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Fig 1. 100 µM diazoxide is not toxic for FRDA lymphoblastoid cells.  
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Fig 2. Diazoxide induces FXN in cultured FRDA lymphoblastoid cells.  
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Fig 3. Diazoxide induces FXN and NRF2 expression in YG8sR cerebellum and heart tissues.  
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Fig 4. Diazoxide induces FXN in YG8sR cerebellum, brain and heart tissues.    
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Fig 5. Diazoxide decreases oxidative stress in YG8sR mice.  
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Fig 6. Diazoxide reduces locomotor activity of YG8sR mice.  
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Fig 7. Diazoxide improves YG8sR mice coordination.  
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Fig 8. Diazoxide induces FXN expression through mTOR pathway and NRF2 nuclear translocation in cultured 
FRDA lymphoblastoid cells.  
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